insiderdelta
CoverageForm 410-K10-Q8-K13D13G13F

FULC · Fulcrum Therapeutics, Inc. - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.

Price · FULC

1Y3Y5YMax
Sign in to download
AnnualQuarterly

Income Statement

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Revenue----------
Cost of Revenue----------
Gross Profit----------
R&D----------
SG&A$8.10M-$7.56M$6.83M$7.00M-$8.42M$10.25M$10.06M-
Total Operating Expenses$22.19M-$21.86M$19.82M$20.40M-$25.13M$27.51M$29.83M-
D&A$338.0K-$300.0K$300.0K$353.0K-$400.0K$400.0K$479.0K-
Operating Income($22.19M)-($21.86M)($19.82M)($20.40M)-($25.13M)$52.49M($29.83M)-
Interest Expense----------
Income Tax----------
Net Income($18.89M)-($19.59M)($17.30M)($17.66M)-($21.70M)$55.41M($26.87M)-
EPS - Basic----------
EPS - Diluted----------

Balance Sheet

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Cash & Equivalents$50.26M$197.53M$47.08M$42.59M$42.18M$58.21M$72.63M$86.70M$39.95M$25.56M
Accounts Receivable----------
Inventory----------
Accounts Payable$2.45M$1.59M$2.86M$1.75M$1.51M$1.16M$4.04M$3.58M$3.86M$2.76M
Current Assets$338.67M$357.48M$205.86M$219.37M$232.56M$249.92M$267.49M$280.29M$217.95M$242.20M
Total Assets$346.77M$366.28M$214.86M$228.84M$242.65M$260.72M$279.01M$294.26M$232.59M$257.69M
Current Liabilities$9.86M$13.05M$11.63M$8.98M$8.10M$11.04M$14.51M$12.70M$10.69M$13.68M
Long-term Debt----------
Total Liabilities$13.47M$17.28M$16.49M$14.46M$14.16M$17.68M$21.72M$20.47M$19.00M$22.50M
Stockholders' Equity----------
Retained Earnings----------

Cash Flow

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Operating Cash Flow($18.75M)---($15.26M)---($25.28M)-
Investing Cash Flow($128.21M)---($777.0K)---$38.13M-
Financing Cash Flow($312.0K)---$0---$1.65M-
CapEx$8.0K---$0---$28.0K-
Free Cash Flow($18.76M)---($15.26M)---($25.31M)-

Ratios

MetricQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Profitability
Gross margin----------
Operating margin----------
EBITDA margin----------
Net margin----------
Free cash flow margin----------
FCF / Net income0.99---0.86---0.94-
R&D / Revenue----------
SG&A / Revenue----------
Effective tax rate----------
Return on assets-5.4%--9.1%-7.6%-7.3%--7.8%18.8%-11.6%-
Return on equity----------
Return on invested capital----------
Liquidity
Current ratio34.3327.4017.7024.4228.7122.6318.4422.0720.3817.71
Quick ratio34.3327.4017.7024.4228.7122.6318.4422.0720.3817.71
Cash ratio5.1015.144.054.745.215.275.016.833.741.87
Leverage
Debt / Equity----------
Debt / Assets----------
Debt / EBITDA----------
Interest coverage----------
Equity multiplier----------
Liabilities / Assets0.040.050.080.060.060.070.080.070.080.09
Efficiency
Asset turnover----------
Inventory turnover----------
Days sales outstanding----------
Days inventory outstanding----------
Days payable outstanding----------
Cash conversion cycle----------
Valuation
P / E----------
P / B----------
P / S----------
EV / EBITDA----------
Growth
Revenue growth (YoY)----------
Revenue CAGR (3y)----------
Revenue CAGR (5y)----------
Gross profit growth (YoY)----------
Operating income growth (YoY)-8.7%-13.0%-31.6%-8.4%--9.3%-
Net income growth (YoY)-7.0%-9.7%-34.3%-9.7%--13.0%-
EPS growth (YoY)----------
EPS CAGR (3y)----------
EPS CAGR (5y)----------
FCF growth (YoY)-22.9%---39.7%----4.2%-
FCF CAGR (5y)----------
Book value growth (YoY)----------

Peer comparison

Same SIC group: Pharmaceutical Preparations

CompanyRevenue (last FY)Net marginROE
LLY$65.18B31.7%77.8%
UTHR$3.18B41.9%18.8%
PFE$62.58B12.4%9.0%
ZTS$9.47B28.2%80.2%
VRTX$12.00B32.9%21.2%

Comparing Fulcrum Therapeutics against the 5 most active filers in the same SIC group.